Mineralys Therapeutics Inc (NASDAQ: MLYS) is -24.94% lower on its value in year-to-date trading and has touched a low of $7.95 and a high of $16.91 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MLYS stock was last observed hovering at around $9.50 in the last trading session, with the day’s loss setting it -0.26%.
Currently trading at $9.24, the stock is -19.77% and -25.01% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.23 million and changing -2.74% at the moment leaves the stock -26.04% off its SMA200. MLYS registered 6.08% gain for a year compared to 6-month loss of -32.16%. The firm has a 50-day simple moving average (SMA 50) of $12.3212 and a 200-day simple moving average (SMA200) of $12.49295.
The stock witnessed a -24.01% gain in the last 1 month and extending the period to 3 months gives it a -33.72%, and is -6.38% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.01% over the week and 8.03% over the month.
Mineralys Therapeutics Inc (MLYS) has around 28 employees, a market worth around $459.86M and $0.00M in sales. Distance from 52-week low is 16.23% and -45.34% from its 52-week high. The company has generated returns on investments over the last 12 months (-64.68%).
The EPS is expected to shrink by -85.49% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Mineralys Therapeutics Inc (MLYS) Top Institutional Holders
153.0 institutions hold shares in Mineralys Therapeutics Inc (MLYS), with institutional investors hold 103.60% of the company’s shares. The shares outstanding are 49.76M, and float is at 23.57M with Short Float at 7.75%. Institutions hold 100.98% of the Float.
Mineralys Therapeutics Inc (MLYS) Insider Activity
The most recent transaction is an insider sale by Levy Adam Scott, the company’s CFO and Secretary. SEC filings show that Levy Adam Scott sold 10,757 shares of the company’s common stock on Jan 13 ’25 at a price of $9.10 per share for a total of $97864.0. Following the sale, the insider now owns 0.23 million shares.
Mineralys Therapeutics Inc disclosed in a document filed with the SEC on Jan 13 ’25 that Congleton Jon (Chief Executive Officer) sold a total of 18,333 shares of the company’s common stock. The trade occurred on Jan 13 ’25 and was made at $9.06 per share for $0.17 million. Following the transaction, the insider now directly holds 0.88 million shares of the MLYS stock.
Still, SEC filings show that on Jan 13 ’25, Congleton Jon (Officer) Proposed Sale 18,333 shares at an average price of $9.06 for $0.17 million. The insider now directly holds shares of Mineralys Therapeutics Inc (MLYS).
